Home Featured Page 161

Featured

Latest

ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics

Evelyn Eddy Shoop MSN, APRN, PMHNP-BC: Lived Experience, Qualitative Data, and the Future of Psychedelic Care

Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b Debrief; UK Government Responds to MPs’ Psilocybin-Related Questions

Dr Jason Konner – Psychedelic Oncology and the Future of Cancer Care

The Psychedelic News Feed: November 3 – 9, 2025

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research...

PT334 – Prof. David Nutt – The Human Brain, Addiction, and...

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis...

PT333 – Miriam Volat, MS & T. Cody Swift, MFT –...

FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT OF UNITS AND CONVERTIBLE DEBENTURE UNITS...

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as...

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge...

Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation

1...160161162...302 Page 161 of 302

ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting...

Evelyn Eddy Shoop MSN, APRN, PMHNP-BC: Lived Experience, Qualitative Data, and...

Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.